IL158201A0 - Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine - Google Patents

Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine

Info

Publication number
IL158201A0
IL158201A0 IL15820102A IL15820102A IL158201A0 IL 158201 A0 IL158201 A0 IL 158201A0 IL 15820102 A IL15820102 A IL 15820102A IL 15820102 A IL15820102 A IL 15820102A IL 158201 A0 IL158201 A0 IL 158201A0
Authority
IL
Israel
Prior art keywords
cox
inhibitor
drug
solvent
pharmaceutical composition
Prior art date
Application number
IL15820102A
Other languages
English (en)
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of IL158201A0 publication Critical patent/IL158201A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL15820102A 2001-04-17 2002-04-12 Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine IL158201A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28438101P 2001-04-17 2001-04-17
US32695201P 2001-10-04 2001-10-04
PCT/US2002/011689 WO2002083177A1 (en) 2001-04-17 2002-04-12 Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine

Publications (1)

Publication Number Publication Date
IL158201A0 true IL158201A0 (en) 2004-05-12

Family

ID=26962574

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15820102A IL158201A0 (en) 2001-04-17 2002-04-12 Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine

Country Status (18)

Country Link
US (1) US20030105141A1 (es)
EP (1) EP1379279A1 (es)
JP (1) JP2004530669A (es)
KR (1) KR20040018355A (es)
CN (1) CN1516601A (es)
AR (1) AR033221A1 (es)
AU (1) AU2002305175B2 (es)
BR (1) BR0208994A (es)
CA (1) CA2444220A1 (es)
CZ (1) CZ20032792A3 (es)
EA (1) EA008103B1 (es)
IL (1) IL158201A0 (es)
MX (1) MXPA03009411A (es)
NO (1) NO20034629L (es)
NZ (1) NZ528741A (es)
PE (1) PE20021145A1 (es)
PL (1) PL364524A1 (es)
WO (1) WO2002083177A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
EP1344523A1 (en) * 2002-03-11 2003-09-17 Warner-Lambert Company Ibuprofen solution for hard gelatin capsules
IL164163A0 (en) * 2002-04-09 2005-12-18 Pharmacia Corp Process for preparing a finely self-emulsifiable pharmaceutical composition
WO2004073492A2 (en) * 2003-02-14 2004-09-02 Massachusetts Eye And Ear Infirmary Chlamydia pneumoniae associated chronic intraocular disorders and treatment thereof
DK2279729T3 (da) * 2003-07-17 2016-11-28 Banner Life Sciences Llc Præparater med kontrolleret frigivelse
EP1510206A1 (en) * 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
CA2569964A1 (en) * 2004-06-10 2005-12-29 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
CN101142198B (zh) 2005-02-17 2012-10-31 辛塔制药公司 用于治疗疾病的异*唑坎布雷它斯丁衍生物
CA2627292C (en) 2005-10-26 2012-04-17 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system
JP5406529B2 (ja) 2005-10-26 2014-02-05 バナー ファーマキャプス， インコーポレイテッド カプセル充墳物としての親油性ベヒクルに基づく二重制御された放出マトリクスシステム
EP2207531B1 (en) * 2007-09-27 2012-04-04 Wockhardt Limited Self-emulsifying pharmaceutical compositions of rhein or diacerein
CN105363037B (zh) * 2008-12-03 2019-02-05 安斯泰来德国有限公司 苯达莫司汀的口服剂型
US9717703B2 (en) 2009-10-16 2017-08-01 Glaxosmithkline Llc Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed
JO3659B1 (ar) 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
BR112012030654B1 (pt) * 2010-06-02 2021-11-09 Astellas Deutschland Gmbh Composição farmacêutica para administração oral compreendendo bendamustina ou um sal farmaceuticamente aceitável da mesma, como um ingrediente ativo, e um excipiente farmaceuticamente aceitável
EP2392319A1 (en) * 2010-06-04 2011-12-07 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical compositions of co-crystals of tramadol and coxibs
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
TW201322979A (zh) * 2011-10-18 2013-06-16 Raqualia Pharma Inc 醫藥組成物
SG11201505247TA (en) * 2013-01-14 2015-08-28 Infirst Healthcare Ltd Solid solution compositions and use in cardiovascular disease
KR20150129664A (ko) * 2013-02-04 2015-11-20 인퍼스트 헬스케어 리미티드 만성 염증 및 염증성 질병을 치료하기 위한 조성물 및 방법
WO2015031198A2 (en) 2013-08-27 2015-03-05 Voudouris Vasilios Bendamustine pharmaceutical compositions
CR20190052A (es) 2016-07-05 2019-05-03 Golden Renewable Energy Llc Sistema y proceso para convertir plástico desechable en combustible
US12213510B2 (en) 2019-09-11 2025-02-04 Nicoventures Trading Limited Pouched products with enhanced flavor stability
CN113750043A (zh) * 2021-09-18 2021-12-07 山东省药学科学院 一种塞来昔布自乳化口服液及其制备方法
WO2024142089A1 (en) * 2022-12-27 2024-07-04 Cipla Limited Injectable compositions of celecoxib

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO118291B1 (ro) * 1993-11-30 2003-04-30 Searle & Co Derivati de pirazol 1,3,4,5 - tetrasubstituiti si compozitie farmaceutica care ii contine
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5733909A (en) * 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
EP1007049A1 (en) * 1997-08-27 2000-06-14 Hexal AG New pharmaceutical compositions of meloxicam with improved solubility and bioavailability
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
AR035642A1 (es) * 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor
JP2004503588A (ja) * 2000-07-13 2004-02-05 ファルマシア・コーポレーション 全身性疼痛および頭痛に対する選択的シクロオキシゲナーゼ−２阻害薬および血管調節化合物

Also Published As

Publication number Publication date
US20030105141A1 (en) 2003-06-05
BR0208994A (pt) 2004-04-27
EP1379279A1 (en) 2004-01-14
NZ528741A (en) 2005-09-30
AU2002305175B2 (en) 2007-07-12
EA008103B1 (ru) 2007-04-27
CN1516601A (zh) 2004-07-28
JP2004530669A (ja) 2004-10-07
CZ20032792A3 (cs) 2004-04-14
EA200301019A1 (ru) 2004-06-24
PE20021145A1 (es) 2003-01-16
CA2444220A1 (en) 2002-10-24
MXPA03009411A (es) 2004-01-29
KR20040018355A (ko) 2004-03-03
PL364524A1 (en) 2004-12-13
AR033221A1 (es) 2003-12-10
NO20034629L (no) 2003-12-10
NO20034629D0 (no) 2003-10-16
WO2002083177A1 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
IL158201A0 (en) Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine
IL216686A (en) Ritonavir-containing drug solution and organic solvent containing a mixture of long fatty acids and water
CY2013023I1 (el) Φαρμακο για την υπερδραστηρια ουροδοχο κυστη περιλαμβανον παραγωγο ανιλιδιου οξικου οξεος ως το ενεργο συστατικο
NO20040178L (no) Farmasoytisk formulering innebefattende en protonpumpeinhibitor og syrenoytraliserende midler
NO20031797D0 (no) Heteroarylalkylpiperazinderivater som fettsyreoksydasjonsinhibitorer
LU92419I2 (fr) Riociguat et ses dérivés pharmaceutiquement acceptables (ADEMPAS®)
SI1245568T1 (sl) Sulfonilni derivati aminokislin in njihova uporaba kot inhibitorji depeptidil-peptidaze iv (dpp iv)
HRP20040545A2 (en) Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
IL158200A0 (en) Orally deliverable pharmaceutical composition comprising an active compound having an aminosulfonyl group (cox-2 inhibitor), a polyethylene glycol and a free-radical scavenging antioxidant
IL146914A0 (en) Pharmaceutical compositions containing (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives
AU2001288998A1 (en) Pharmaceutical formulations containing a non-steroidal antiinflammatory drug anda proton pump inhibitor
NO20040564L (no) Karboksylsyrederivatforbindelser og legemidler omfattende disse forbindelser som den aktive bestanddel
EP1246608A4 (en) PHARMACEUTICAL PREPARATIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES WITH LOW WATER SOLUBILITY
ATE337793T1 (de) Dispergierbare pharmazeutische zusammensetzung eines entzündungshemmers
CY1114210T1 (el) Απο του στοματος μορφη δοσολογιας περιλαμβανουσα αναστολεα pde 4 ως δραστικο συστατικο και πολυβινυλοπυρρολιδονη ως εκδοχο
HUP0700105A2 (en) Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
AR079399A2 (es) Procedimientos para preparar bifenazato
WO2004009583A3 (en) Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor
IL170316A (en) Cycloalkyl-methoxy substituted acetic acid derivatives and pharmaceutical compositions comprising them
IL172167A0 (en) Pharmaceutically useful salts of carboxylic acid derivatives
AU3408901A (en) Cancer remedy comprising anthranilic acid derivative as active ingredient
AU2001234089A1 (en) Cancer remedy comprising anthranilic acid derivative as active ingredient
HUP0303694A3 (en) Aza-amino acid derivatives and pharmaceutical
HUP0302534A3 (en) Preparation of mandelic acid derivatives
GB2398005B (en) Orally administrable pharmaceutical formulation